Global Diabetic Nephropathy Market
Market Size in USD Billion
CAGR :
% 
USD
3.74 Billion
USD
6.09 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 3.74 Billion |
 Market Size (Forecast Year) |
USD 6.09 Billion |
 CAGR |
% |
| Major Markets Players |
Global Diabetic Nephropathy Market Segmentation, By Drug Class (Diuretics, Antioxidant Inflammation Modulator, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Renin Inhibitors, Calcium Channel Blockers, Others), Type (Type-1 Diabetes and Type-2 Diabetes), Route of Administration (Oral, Parental, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2032
Diabetic Nephropathy Market Analysis
The global diabetic nephropathy market is expected to witness significant growth during the forecast period. The factors primarily driven the growth of global diabetic nephropathy market are high prevalence of diabetes as diabetic nephropathy is a very common indication and presence of diabetic management centres. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Global Diabetic Nephropathy Market Size
Global diabetic nephropathy market size was valued at USD 3.74 billion in 2024 and is projected to reach USD 6.09 billion by 2032, with a CAGR of 6.30% during the forecast period of 2025 to 2032.
Global Diabetic Nephropathy Market Trends
"Increasing Adoption of Targeted Therapies and Early Diagnosis"
One of the key trends in the global diabetic nephropathy market is the increasing adoption of targeted therapies and early diagnostic tools. As awareness of diabetic nephropathy grows, there is a greater focus on early detection and personalized treatment options to slow or prevent kidney damage. New advancements in medication, such as SGLT-2 inhibitors and other novel therapies, are gaining popularity due to their effectiveness in managing diabetic nephropathy and improving patient outcomes. Additionally, the rise in non-invasive diagnostic methods, like biomarkers and advanced imaging techniques, is making early diagnosis more accessible. With the growing prevalence of diabetes and the increasing emphasis on managing complications before they become severe, these trends are expected to drive the demand for diabetic nephropathy treatments. Furthermore, the aging population and increasing healthcare access in developing countries are likely to continue fueling market growth.
Report Scope and Market Segmentation
|
Attributes |
Diabetic Nephropathy Key Market Insights |
|
Segmentation |
|
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Key Market Players |
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Bristol Myers Squibb Company (U.S.) GlaxoSmithKline Plc. (U.S.), Bayer AG (Germany) |
|
Market Opportunities |
|
Diabetic Nephropathy Market Definition
Diabetic nephropathy is also termed as diabetic kidney disease characterized by development of hypertension and hyperglycaemia which induces the changes in the multiple pathways that contribute to morphological changes in the kidneys and eventually leads to the kidney damage. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Diabetic Nephropathy Market Dynamics
Drivers
- Rising Awareness For Disease Treatment
Rising awareness among patients and healthcare professionals for the treatment of diabetes and more and more usage of combination therapy are the driving factors that is expected to boost the demand for global diabetic nephropathy market during the forecast period of 2025-2032.
- Increased Clinical Studies and Government Initiatives
The global diabetic nephropathy market is estimated to be driven by the rising R&D investments in drug discovery and development and the rising prevalence of diabetes. For instance, as per the reports of International Diabetes Federation, around 415 million people are currently affected by diabetes globally and it is hoped to increase to 642 million diabetic people by the year 2040.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increasing Demand for angiotensin-converting enzyme inhibitors
The angiotensin-converting enzyme inhibitors are widely used due to increase in number of temporary as well as permanent chronic heart disease, hypertension heart attack, and diabetic nephropathy. Thus, it boosts the market growth.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global diabetic nephropathy market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global diabetic nephropathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global diabetic nephropathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Diabetic Nephropathy Market Scope
The global diabetic nephropathy market is segmented on the basis of drug class, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Diuretics
- Antioxidant Inflammation Modulator
- Angiotensin Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
- Renin Inhibitors
- Calcium Channel Blockers
- Others
Type
- Type-1 Diabetes
- Type-2 Diabetes
Route of Administration
- Oral
- Parental
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Diabetic Nephropathy Market Regional Analysis
The global diabetic nephropathy market is analyzed and market size insights and trends are provided by type, drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global diabetic nephropathy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to increasing infection in geriatric population, and growing population with cardiovascular diseases.
Asia-Pacific is expected to grow at a significant growth rate over the forecast period of 2025 to 2032 increased prevalence of lung infections and associated diseases and increasing initiatives taken by the government and pharmaceutical organizations to spread awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Diabetic Nephropathy Market Share
The global diabetic nephropathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global diabetic nephropathy market.
Diabetic Nephropathy Market Leaders Operating in the Market Are:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bristol Myers Squibb Company (U.S.)
- GlaxoSmithKline Plc. (U.S.)
- Bayer AG (Germany)
Latest Developments in Diabetic Nephropathy Market
- In January 2025, the U.S. Food and Drug Administration (FDA) approved Ozempic® (semaglutide) as the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This approval is based on the pivotal FLOW phase 3b kidney outcomes trial, which demonstrated a 24% relative risk reduction in kidney disease progression and cardiovascular and kidney mortality compared to placebo
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
